Context: Carbohydrate-restricted diets may increase low-density lipoprotein cholesterol and thereby cardiovascular risk. Objective: A systematic review and meta-analyses were conducted to compare the effects of very low, low, and moderate carbohydrate, higher fat diets versus high-carbohydrate, low-fat diets on low-density lipoprotein cholesterol and other lipid markers in overweight/ obese adults. Data Sources: Medline, PubMed, Cochrane Central, and CINAHL Plus were searched to identify large randomized controlled trials (n > 100) with duration ! 6 months. Data Extraction: Eight randomized controlled trials (n ¼ 1633; 818 carbohydrate-restricted diet, 815 low-fat diet) were included. Data Analysis: Quality assessment and risk of bias, a random effects model, and sensitivity and subgroup analyses based on the degree of carbohydrate restriction were performed using Cochrane Review Manager. Results were reported according to the Preferred Reporting Items for Systematic Reviews and MetaAnalysis Protocol. Results: Carbohydrate-restricted diets showed no significant difference in low-density lipoprotein cholesterol after 6, 12, and 24 months. Although an overall pooled analysis statistically favored low-fat diets (0.07 mmol/L; 95% confidence interval [CI], 0.02-0.13; P ¼ 0.009], this was clinically insignificant. High-density lipoprotein cholesterol and plasma triglycerides at 6 and 12 months favored carbohydrate-restricted diets (0.08 mmol/L; 95%CI, 0.06-0.11; P < 1 Â 10 À5 and À0.13 mmol/L; 95%CI, À0.19 to À0.08; P < 1 Â 10 À5 , respectively). These favorable changes were more marked in the subgroup with very-low carbohydrate content (< 50 g/d; 0.12 mmol/L; 95%CI, 0.10-0.14; P < 1 Â 10 À5 and À0.19 mmol/L; 95%CI, À0.26 to À0.12; P ¼ 0.02, respectively). Conclusions: Large randomized controlled trials of at least 6 months duration with carbohydrate restriction appear superior in improving lipid markers when compared with low-fat diets. Dietary guidelines should consider carbohydrate restriction as an alternative dietary strategy for the prevention/management of dyslipidemia for populations with cardiometabolic risk.
INTRODUCTION
The galloping global upward trend in obesity/overweight prevalence and epidemics of noncommunicable diseases 1 is raising concern regarding the efficiency of existing dietary recommendations. Questions on the strength of the evidence on which these recommendations are based, 2, 3 as well as the role of saturated fatty acids (SFAs), polyunsaturated fatty acids (PUFAs), and refined carbohydrates in the onset of cardiovascular disease (CVD), have historically been and continue to be debated. [4] [5] [6] [7] [8] [9] Recent evidence suggests that carbohydraterestricted diets (CRDs), including low, moderate, and very-low-carbohydrate ketogenic diets (LCD, MLCD, VLCD, respectively), have the potential to improve various metabolic pathways, with added beneficial effects in treatment of overweight/obesity and in amelioration of cardiometabolic risk markers. [9] [10] [11] [12] [13] [14] Very-lowcarbohydrate diets are often simply referred to as ketogenic diets (KDs). The underlying mechanism of a KD is reduction in the levels of circulating insulin along with increased levels of glucagon due to scarcity of dietary carbohydrates, leading to a reduction in lipogenesis and fat accumulation. [15] [16] [17] This results in increased mobilization of fatty acids from adipocytes and overproduction of ketone bodies, which are used as an alternative fuel to glucose by extrahepatic tissues such as the brain and muscle. [15] [16] [17] [18] Ketone bodies also reduce the catabolism of lean body mass, which, in large, explains the preservation of lean tissue observed during very-low-carbohydrate dieting. 12, 19 The main concern regarding CRDs, which are potentially high in total fatty acids and SFAs, is their theoretically adverse effect on low-density lipoprotein cholesterol (LDL-C) levels and, presumably, CVD risk. Saturated fat per se is not associated with increased CVD risk, as concluded in several recent meta-analyses and systematic reviews 6, 20, 21 due, to some extent, to the differential effects of saturated fat on LDL subclass concentrations. Namely, cholesterol-enriched large buoyant LDL particles (lbLDLs) have been shown to be less atherogenic, whereas small dense (sdLDLs) and mediumsized LDL particles more strongly associate with CVD outcomes. [22] [23] [24] [25] [26] Data suggest that a shift toward lbLDL occurs among participants following a CRD, resulting in a decreased CVD risk, whereas the opposite occurs among those on high-carbohydrate diets. 27 However, the role of CRDs in the long-term management of obesity and cardiometabolic risk markers is not well established. Data from recent systematic reviews and metaanalyses regarding LDL-C are very contradictory. Whereas some find an increased level, [28] [29] [30] others found non-statistically significant changes 31 or decreased levels 32 of LDL-C in participants following a CRD compared with those on low-fat diets (LFDs).
Due to the lack of consensus on the effects of CRDs on LDL-C, authors have been very cautious in making recommendations for or against them. This has also led to deepening disagreement among experts 2 and further uncertainty for the public, especially regarding the long-term effectiveness of CRDs, pointing toward the need to further reconsider and evaluate the existing scientific evidence. The lack of consensus could be partially assigned to the heterogeneity of the carbohydrate (CHO) content in interventions because definitions of CRDs differ, 14 and/or in inclusion and exclusion criteria used during the selection procedures of performed meta-analyses. For example, some meta-analyses include trials of both healthy and diabetic patients, 32 and many report only the pooled net effect of large and small trials without stratification by duration of intervention or followup. [28] [29] [30] Small studies may overestimate intervention effects, introduce higher heterogeneity, and increase risk of selection bias, [33] [34] [35] [36] whereas larger studies are considered to have more power to detect differences in observed outcomes and are more likely to generate conclusions that can be generalized. 37 Based on these limitations, Santos et al 38 performed a meta-analysis of randomized controlled trials (RCTs) with at least 100 overweight/obese healthy participants. This study found an initial increase of LDL-C in the period 0-6 months, followed by a significant decrease at 12-23 months (P ¼ 0.02) and 24 months (P ¼ 0.03), and an overall significantly favorable effect of the CRD on HDL-C (P ¼ 0.00001) and plasma triglycerides (TG) (P ¼ 0.00001). Although well designed and important, the limitation of this meta-analysis lies in the fact that the final effects are compared with the baseline values with no comparison against LFDs.
In light of these shortcomings and contradictory findings, the aim of this systematic review and metaanalysis is to compare the effects of CRDs and LFDs on LDL-C and other lipid markers in overweight/obese adults, using data obtained from large RCTs with a duration of at least 6 months. This research also aims to elucidate the choice of diet that would be most effective for prevention and management of dyslipidemia in population groups at higher risk of cardiovascular disease (eg, those with obesity, overweight, metabolic syndrome, type 2 diabetes) and to contribute to the discussion about whether current dietary guidelines should be reconsidered and adapted to the latest evidence.
METHODS
This systematic review and meta-analysis was performed and reported according to the Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) Statement 39 (Appendix S1 in the Supporting Information online), and PICOS (Population, Intervention, Comparison, and Outcomes) ( Table 1 ) criteria were used to define the following research question: Do long-term carbohydrate-restricted, higher-fat diets have an adverse effect on LDL-C levels and presumably CVD risk among overweight/obese adults?
Search methods
Medline (EBSCO), PubMed, Cochrane Central, and CINAHL Plus were searched for relevant RCTs published between January 1970 and June 2017 with no restriction on language. These databases were searched individually with advanced search strategies using various combinations of filters and controlled vocabulary in relation to both CRDs and LFDs in order to enhance precision and sensitivity (Appendix S2 in the Supporting Information online). Furthermore, previous relevant meta-analyses, systematic reviews, and selected RCTs were manually searched for studies that met the inclusion/exclusion criteria.
Inclusion criteria and data abstraction
Randomized controlled trials included in this research were required to compare the effects of CRDs (defined as 45% total energy intake (TEI) from CHO, including MLCD 45% to >26% TEI or 130-225 g, LCD 10% to < 26% TEI or 50-130 g, and VLCD <10% TEI or <50 g, and >35% TEI from fat, fed ad libitum) versus LFDs (defined as 35% TEI from fat, !50% TEI from CHO, and restriction on total energy intake) 40 ,41 on serum/plasma LDL-C and other lipid profile markersnamely, total cholesterol (TC), high density lipoproteincholesterol (HDL-C), and triglycerides (TG). Reports on the trials were published between 1970 and June 2017. Large RCTs with a duration of at least 6 months and with at least 100 randomized adult participants (aged 18-65 y) at the start of the dietary intervention, with a body mass index (BMI) > 25 kg/m 2 were included. The decision to include RCTs with a duration of at least 6 months was based on the differential effects on LDL-C in shorter term versus longer term studies and lack of comparison with LFDs at this duration (ie, compared with baseline, LDL-C increases at 6 months but decreases at 12 and 24 months). 38 
Exclusion criteria
To increase power and reduce heterogeneity and selection bias, [33] [34] [35] 37 trials with a study population <100 randomized participants were excluded. Trials that included participants with a specific pathology other than obesity (such as diabetes, cancer, kidney disease, or coronary heart disease) or an altered endocrinological state (such as pregnancy, lactation, or menopause) trials with a duration of <6 months, and trials for which standard deviation (SD) or 95% confidence intervals (CIs) were not reported were also excluded.
Data extraction and quality assessment
To minimize potential bias during the selection procedure, duplicates of full articles retrieved for further assessment were independently read by 2 reviewers to make a consensus decision for inclusion. From studies with more than 2 interventions, the most suitable dietary interventions were chosen for comparison. The following data were collected: title; first author; year of publication; country; design of RCT (parallel, crossover, factorial); blinding of participant and personnel (open, single, double); baseline characteristics of study participants, such as age, sex, BMI, total number of randomized participants, health status, and baseline LDL-C, HDL-C, TG, and TC values; composition of diet; attrition; handling of missing data; and overall and subgroup mean difference in outcomes with measures of variance (SD or 95%CI). The Cochrane Collaboration tool 42 was used for assessing methodological quality and risk of bias with the following categories: selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel and blinding of the outcome assessment), reporting bias (selective outcome reporting), and other biases. Publication bias was assessed with funnel plots. Disagreements were resolved by discussion and by seeking the opinion of the third independent reviewer, as required by the PRISMA statement. 39 
Data synthesis and data analysis
Extracted data from eligible studies were first tabulated by outcome of interest and presented in millimoles per liter (mmol/L); data expressed in milligrams per deciliter (mg/dL) were converted into millimoles per liter by multiplying the values with the factor 0.0259 for cholesterol and its fractions, and the factor 0.013 for conversion of TG. In studies for which mean values and 95%CI were reported, the SD was calculated. Intervention effects across trials were pooled to calculate weighted mean differences and the 95%CI for each continuous outcome (LDL-C, HDL-C, TG, TC) between baseline and 6, 12, and 24 months of intervention duration. The CRD arm was also divided into 2 subgroups based on the CHO content: VLCD with <10% CHO TEI (<0 g CHO) and MLCD with 26%-45% CHO TEI (130-225 g CHO). 43 Subgroup analyses were performed when possible to explore the potential effect of different CHO content on the primary and secondary outcome estimates. No studies classified as LCDs (10% to <26% CHO TEI ) that would fulfill the inclusion criteria were identified. The random effects model was used to account for heterogeneity in design and outcome variables, as the heterogeneity is incorporated in the total weighted efficacy of treatment, allowing for a greater variability of the estimate. 44 Heterogeneity and inconsistency (I 2 ) was calculated with the Cochran Q test. I 2 values >50% and >75% indicated moderate and high heterogeneity, respectively. 42 To evaluate the relative influence on the pooled estimated effects, a sensitivity analysis was conducted by excluding studies that had <70% completion rate, studies with a very-low-fat diet, studies that were performed on women only, and studies with the lowest mean age of participants. For detecting the existence of publication bias and its possible effect on the performed metaanalysis, funnel plots were used. All statistical analyses were performed using Review Manager (RevMan 5.3.5).
RESULTS

Literature search
The flow of the study selection procedure that followed the literature search is summarized in Figure 1 . Potential relevant records (n ¼ 308) were identified during the search of the databases, and an additional 17 were identified from screening of references. After initial screening and duplicate removal, 252 records remained, of which 205 were excluded on the bases of interrogation of abstracts. Forty-seven full-text articles were retrieved for detailed review. Thirty-nine full-text records did not fulfill the set inclusion criteria and, after their removal, 8 RCTs remained eligible to be included in the metaanalysis. The reasons for exclusion of the 39 full-article trials are presented in Table 2 . Five trials [45] [46] [47] [48] [49] did not include LDL-C as an outcome; 10 trials [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] were performed on participants with diabetes mellitus and/or CVD; 11 trials [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] had <100 randomized participants; 3 trials [71] [72] [73] had a duration of <6 months; 2 trials 74,75 did not report on SD or 95%CI; 7 trials [76] [77] [78] [79] [80] [81] [82] were irrelevant with inappropriate intervention; and 1 trial 83 was dismissed based on high attrition rate and high risk of bias.
Study and participant characteristics
The main characteristics of the 8 published articles eligible for meta-analysis are summarized in Table 3 . [84] [85] [86] [87] [88] [89] [90] [91] All 8 RCTs were open and parallel group trials with no possibility for blinding of participants due to the polarity of diets. Intervention duration ranged 6-24 months. Most of the trials offered some form of supportive dietary sessions and professional contact, and participants were encouraged to engage and maintain a certain level of physical activity. However, no record of the level of physical activity was reported for any of the trials. Trials were conducted on both sexes, with a higher proportion of female participants, except for the study by Gardner et al, 88 which was performed only on women. The mean age and BMI of participants varied from 28.2 to 51.5 years and 31.4 to 36.1 kg/m 2 , respectively. For all 8 trials [84] [85] [86] [87] [88] [89] [90] [91] with a total of 1633 participants (n ¼ 818 on CRD, n ¼ 815 on LFD) a follow-up of 6 months was reported; for 5 trials with a total of 1010 participants (n ¼ 505 on CRD, n ¼ 505 on LFD) outcome measures at 12 months were reported 84, 86, 87, 89, 90 ; and for 2 trials with a total of 715 participants (n ¼ 357 on CRD, n ¼ 358 on LFD) data for 24 months were reported. 86, 91 According to the CHO content, the CRD intervention was divided into 2 subgroups: VLCD and MLCD (Table  3 ). The VLCD subgroup consisted of 4 trials: 3 trials 86, 88, 90 followed the Atkins diet (Dr. Atkins New Diet Revolution, 1998), 92 defined as <20 g/d of CHO for the first 3 months, with a gradual increase of 5 g/d after the third month up to 50 g/d CHO, whereas in 1 trial 84 the CHO intake was restricted to <40 g of CHO daily. The other 4 trials 85, 87, 89, 91 restricted the CHO consumption to about 35%-40% of the total daily energy; these trials made up the MLCD subgroup. The CRD interventions were ad libitum in all trials regarding energy intake, but some studies found a spontaneous reduction of energy intake. 87, 88, 90 The LFD interventions permitted 50%-65% of energy from CHO and 20% to <35% of energy from fat across all trials, except for the trial of Gardner et al, 88 which had a very-low-fat (<10%), high CHO (70%) intervention (Ornish) diet. 93 Diet compliance was measured via three 24-h dietary recalls 84, 87, 88, 91 or 7-day food diaries. 86, 89, 90 In the Table 2 Reasons for exclusion of full-text trials (n 5 39)
Reason for exclusion Authors
No LDL-C reported Hu et al (2015) 45 McManus et al (2001) 46 Viegener et al (1990) 47 Zelicha et al (2018) 48 Blü her et al (2012) 49 Diabetes mellitus and/or CVD Shai et al (2008) 50 Cardillo et al (2006) 51 Tsai et al (2005) 52 Stern et al (2004) 53 Dyson et al (2007) 54 Samaha et al (2003) 55 Yancy et al (2010) 56 Hu et al (2016) 57 Turer et al (2012) 58 Qi et al (2015) 59 <100 participants on start Lim et al (2010) 60 Das et al (2007) 61 Foster et al (2003) 62 Seshadri et al (2004) 63 Brehm et al (2003) 64 Keogh et al (2007) 65 Ebbeling et al (2007) 66 Bradley et al (2009) 67 Tay et al (2008) 68 Abbreviations: CI, confidence interval; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.
Nutrition Reviews V R Vol. 77 (3):161-180study of Due et al, 85 dietary intake and compliance was assessed by fat biopsy, and food was available from a custom-made supermarket for the purpose of the trial with supervised shopping. Attrition rate showed large variation, with dropout rates ranging 12%-44%. All studies had applied intention-to-treat analysis for the missing data (Table 3) . Reported baseline mean levels of LDL-C, HDL-C, TG, and TC varied across trials and intervention but were well balanced in both the CRD and LFD intervention arms in each study (Table 4 84-91 ). The LDL-C concentrations were directly measured except in the trials of Bazzano et al 84 and Due et al, 85 where it was calculated using the Friedewald formula. 94 In the study of Klemsdal et al, 89 the method of LDL-C assessment was not clearly stated. Three studies evaluated additional lipid profile markers that are of interest to the primary outcome: changes in LDL peak density (g/L) were reported by Morgan et al 90 ; apolipoprotein-B (apo-B) concentration was reported in the trial of Klemsdal et al 89 ; and concentration of the very-lowdensity lipoprotein cholesterol (VLDL-C) fraction was reported in the study of Foster et al. 86 
Quality assessment and risk of bias
The quality and the risk of bias (%) across all included studies were assessed using the Cochrane Risk of Bias Tool and are presented in Figures 2 and 3 . [84] [85] [86] [87] [88] [89] [90] [91] The methods of sequence generation [89] [90] [91] and allocation concealment 86,89,90 used were not clearly reported for 3 studies. Blinding of participants was impossible due to the nature of the trial. In addition, there was no blinding of the outcome assessors reported, but considering the fact that all outcomes are objective, it is unlikely that this influenced the results of the RCTs. There was no evidence of selective reporting, and 5 trials [84] [85] [86] [87] [88] showed low risk of attrition bias. Four studies 86, [89] [90] [91] were judged to have a low risk of bias, and no study received an overall score of "high" in any assessed risk-ofbias category.
Meta-analyses
Effects of carbohydrate-restricted diets and low-fat diets on low-density lipoprotein cholesterol levels. Results from the primary meta-analysis regarding the mean difference of LDL-C concentration between CRD and LFD intervention at 6, 12, and 24 months (compared with baseline) are presented in Figure 4 84-91 and Table S1 in the Supporting Information online. Although participants on the CRD intervention experienced a greater increase in LDL-C compared with those on the LFD intervention, these changes were not statistically significant regardless of intervention duration (6 months: 0.08 mmol/L; 95%CI, À0.01 to 0.18; P ¼ 0.08; 12 months: 0.04 mmol/L; 95%CI, À0.04 to 0.12; P ¼ 0.37; 24 months: 0.10 mmol/L; 95%CI, À0.01 to 0.21; P ¼ 0.06). However, analysis of the global pooled effect between CRD and LFD interventions on LDL-C levels shows a significant weighted mean difference in favor of the LFD (0.07 mmol/L; 95%CI, 0.02-0.13; P ¼ 0.009). Significant (moderate) heterogeneity (I 2 ¼ 58%; P ¼ 0.009) for the estimated difference of LDL-C between both diets was observed only at 6 months. Sensitivity analysis (exclusion of studies one by one) was carried out to identify the possible studies that could explain this heterogeneity. After exclusion of the study of Foster et al, 86 which had the highest weight effect, the heterogeneity considerably decreased (I 2 ¼ 28%; P ¼ 0.22) but did not significantly change the weighted mean difference of LDL-C (P ¼ 0.25). Exclusion of the study of Due et al 85 did not change the heterogeneity but resulted in a statistically significant mean difference of LDL-C at 6 months in favor of the LFD (I 2 ¼ 58%; P ¼ 0.04). This is possibly because it is the smallest study and/or because it has the lowest mean age of participants of 29.8 years (Table 3) .
Subgroup analyses were performed to explore the possible influence of the CHO content of the CRD intervention on LDL-C levels compared with the LFD interventions. The very-low-carbohydrate subgroup (VLCD) with <10% CHO TEI ( Figure 5 84,86,88,90 and Table S2 in the Supporting Information online) and the moderate carbohydrate subgroup (MLCD) with 35%-45% CHO TEI (Figure 6 85,87,89,91 and Table S3 in the Supporting Information online) did not cause any difference of LDL-C compared with the LFD regardless of duration of intervention. Both CRD interventions, the VLCD and the MLCD, resulted in an overall nonsignificant mean change of LDL-C compared with the LFD intervention, and values were similar to the primary meta-analysis (for VLCD: 0.07 mmol/L; 95%CI, À0.05 to 0.18; P ¼ 0.27; for the MLCD: 0.05 mmol/L; 95%CI, À0.02 to 0.12; P ¼ 0.16).
Effects of carbohydrate-restricted diets and low-fat diets on high-density lipoprotein cholesterol and triglycerides levels. The pooled global mean differences for HDL-C (HDL-C: 0.08 mmol/L; 95%CI, 0.06-0.11; P < 1 Â 10 À5 ) ( Figure 7 84-91 and Table S1 in the Supporting Information online) and TG (À0.13 mmol/L; 95%CI, À0.19 to À0.08; P < 1 Â 10 À5 ) (Figure 8 [84] [85] [86] [87] [88] [89] [90] [91] and Table  S1 in the Supporting Information online) showed an overall more favorable total effect of the CRD intervention. However, the mean differences for both parameters were significant at 6 months (HDL-C: 0.09 mmol/L; 95%CI, 0.06-0.12; P < 1 Â 10
À5
; TG: À0.18 mmol/L; 95%CI, À0.25 to À0.11; P < 1 Â 10
) and 12 months ). The VLCD (Figure 9 84,86,88,90 and Table S2 in Table S2 in the Supporting Information online). Compared with the LFD, the MLCD showed more favorable effects regarding HDL-C and TG only for the initial period of 6 months of intervention duration (HDL-C: 0.06 mmol/L; 95%CI, 0.02-0.10; P ¼ 0.002) and (TG: À0.09 mmol/L; 95%CI, À0.18 to 0.0; P ¼ 0.05) (Figure 11 85,87,89,91 and Figure 12 85, 87, 89, 91 and Table S3 in the Supporting Information online). Based on the overall total effect, the subgroup analyses showed that the VLCD was more effective than the MLCD for HDL-C and TG, suggesting that the amount of CHO in CRD interventions plays an important role and its effect depends on the duration of intervention (Tables S2 and  S3 in the Supporting Information online).
Effects of carbohydrate-restricted diets and low-fat diets on total cholesterol levels. TC as an outcome was reported for only 6 studies, [84] [85] [86] [87] 89, 91 which did not permit a meaningful subgroup analysis based on the CHO content of CRD interventions. The primary metaanalysis for the estimated mean difference of total cholesterol level ( Figure 13 84-87,89,91 and Table S1 in the Supporting Information online) revealed a negligible, but nevertheless more favorable, significant effect of the CRD in the initial 6-months period (À0.01 mmol/L; 95%CI, À0.01 to À0.00; P ¼ 0.02). It is worth noting that, although the estimated mean difference at 12 months was identical to the 6-month value, it was not statistically significant (À0.01 mmol/L; 95%CI, À0.04 to 0.3; P ¼ 0.78). Both diets seemed to show no effect on total cholesterol level after 24 months of intervention (À0.00 mmol/L; 95%CI, À0.01 to 0.00; P ¼ 0.66). The combined total effect of all studies was statistically in favor of the CRD intervention but clinically meaningless (À0.00 mmol/L; 95%CI, À0.01 to 0.00; P ¼ 0.002).
Effects of carbohydrate-restricted diets and low-fat diets on lipid markers not included in the meta-analysis. Results of the LDL peak density in the trial of Morgan et al 90 showed that after 6 months of intervention, this variable decreased within both dietary groups included in this RCT. However, the decrease of the LDL peak density, indicating an increase in LDL particle size, was significantly (P < 0.05) greater than the control (no intervention group) only among participants on the VLCD diet. No significant changes of apo-B after 12 months were found within (P ¼ 0.958) and between (P ¼ 0.482) dietary intervention groups in the trial of Klemsdal et al. 89 Decreases in VLDL-C levels reported by Foster et al 86 were significantly greater in the CRD group than in the LFD group at 6 months (LFD: À0.12 mmol/L; 95%CI, À0.17 to À0.08; vs CRD: À0.23 mmol/L; 95%CI, À0.27 to À0.19; P < 0.001) and 12 months (LFD: À0.09 mmol/L; 95%CI, À0.16 to À0.02; vs CRD: À0.21 mmol/L; 95%CI, À0.27 to À0.19; P ¼ 0.009], but nonsignificant differences were found at Funnel plots and publication bias. Upon visual inspection, all 3 funnel plots (Figures S1-S3 in the Supporting Information online) appeared to be approximately Figure 5 Forest plot for low-density lipoprotein cholesterol changes between very-low-carbohydrate diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; LFD, low-fat diet; SD, standard deviation; VLCD, very-low-carbohydrate diet. Figure 6 Forest plot for low-density lipoprotein cholesterol changes between moderate low-carbohydrate diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; LFD, low-fat diet; MLCD, moderate low-carbohydrate diet; SD, standard deviation.
symmetrical; therefore no evidence of publication bias was found. However, the small number of studies included in this meta-analysis means that the funnel plots must be interpreted very cautiously, and the possibility of publication bias cannot be ruled out.
DISCUSSION
The present meta-analysis of large RCTs with duration of at least 6 months compared the effects of CRDs with different CHO content versus LFDs on LDL-C levels as a primary outcome, and on HDL-C, TG, and TC as secondary outcomes. The primary meta-analysis of the effects of CRDs and LFDs on LDL-C levels showed an overall significant weighted mean difference in favor of the LFDs despite the nonsignificant changes at 6, 12, and 24 months of intervention duration (Figure 4) . However, the subgroup analysis of LDL-C levels based on the CHO content of the CRD arm ( Figures 5 and 6 ), showed nonsignificant net changes for both the VLCD and the MLCD diets throughout the whole observed period (6, 12, and 24 months). Further, participants on CRDs experienced negligible changes of TC levels after 6 months ( Figure 13 ) and more favorable changes on HDL-C and TG at 6 and 12 months (Figures 7 and 8) , resulting in overall more favorable net effects of CRDs compared with the LFD regarding these lipid markers. The comparison between VLCD and MLCD subgroups revealed the VLCD showed a marked increase and decrease of HDL-C and TG, respectively (Figures 9-12) . It is worth noting, however, that the analyses with a follow-up of 24 months included only 2 trials.
The more favorable changes in several lipid parameters (HDL-C and TG) and nonsignificant changes of LDL-C in both the VLCD and MLCD subgroup analysis, despite the slight global increase in LDL-C, support the view that CHO restriction, especially the VLCD, is more effective in improving the investigated CVD risk markers. The present findings with regard to LDL-C, HDL-C, and TG weighted mean changes are relatively consistent with the findings of several other meta-analyses, 28, 32, 95 all concluding that CRDs are at least as beneficial as the LFD and thus proposing CRDs as an alternative tool for treatment of metabolic risk and obesity. These findings are also in line with the most recent meta-analyses by Mansoor et al 29 and Lu et al, 30 which Figure 7 Forest plot for high-density lipoprotein cholesterol changes between carbohydrate-restricted diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; CRD, carbohydrate-restricted diet; HDL-C, highdensity lipoprotein cholesterol; LFD, low-fat diet; SD, standard deviation.
investigated the effects of a CRD versus an LFD on cardiovascular risk markers. Although the Lu et al 30 study showed an increase in LDL-C of 0.11 mmol/L (95%CI, 0.202-0.026) with the CRD, the authors emphasized the beneficial HDL-C-raising effect of the CRD of 0.066 mmol/L (95%CI, 0.10-0.033), equating to a 7.45% reduction in relative risk of CVD. However, Mansoor et al 29 found an overall increase in LDL-C level of 0.16 mmol/L (95%CI, 0.003-0.33) with the CRD and highlighted its possible detrimental effect on CVD, stating this may outweigh the benefits of the increased HDL-C and decreased TG levels observed. The results of the present study show the inverse; the overall increase in LDL-C of 0.07 mmol/L (95%CI, 0.02-0.13) with the CRD in the primary meta-analysis equates to a 1.54% relative risk reduction in cardiovascular events. 96 With HDL-C, the pooled increase of 0.08 mmol/L (95%CI, 0.06-0.11) reduces relative risk by 4.6% (using the latest evidence from the European Atherosclerosis Society). 97 Furthermore, the lack of significant difference for LDL-C at 6, 12, and 24 months and in the VLCD and the MLCD subgroup analysis supports a negated risk of CVD from LDL-C. These differences are presumably due to the different inclusion/exclusion criteria during the selection process between the current and the 2 previous meta-analyses. 29, 30 Targeting LDL-C has been a conventional strategy in prevention and treatment of CVD and reduction of mortality rate 98, 99 using statins that inhibit the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase activity, which decreases hepatic cholesterol production and upregulation of the LDL-receptor. 100 However, the reduction of CVD risk accomplished with this strategy, as found in several clinical trials, 101, 102 is no more than 30%. The main limitations of this strategy lie in the observed atherosclerotic complications among participants, even after reaching acceptable LDL-C goals, 103 which is indicative of the presence of other risk factors beyond LDL-C that should be considered.
Extensive evidence has shown that parameters that take into consideration the role of triglyceride-rich remnant lipoproteins or non-HDL-C as an indicator of cholesterol within all of the apo-B particles (including LDL, VLDL, Lp(a), and to some extent, intermediatedensity lipoprotein, chylomicrons, and chylomicron remnants) are superior to LDL-C in quantifying the Figure 8 Forest plot for triglyceride changes between carbohydrate-restricted diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; CRD, carbohydrate-restricted diet; HDL-C, high-density lipoprotein cholesterol; LFD, low-fat diet; SD, standard deviation. Figure 10 Forest plot for triglycerides changes between very-low-carbohydrate diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; LFD, low-fat diet; TG, triglycerides; SD, standard deviation; VLCD, verylow-carbohydrate diet. Figure 9 Forest plot for high-density lipoprotein cholesterol changes between very-low-carbohydrate diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LFD, low-fat diet; SD, standard deviation; VLCD, very-low-carbohydrate diet.
atherogenic properties of lipoproteins. 104, 105 In that context, non-HDL-C, TG, and the TC/HDL-C ratio are more strongly associated with increased CVD risk than LDL-C, as found in several prospective studies, such as the Lipid Research Clinics Program Longitudinal Follow-up Study with >19 years of follow-up of CVD Figure 11 Forest plot for high-density lipoprotein cholesterol changes between moderate low-carbohydrate diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LFD, low-fat diet; MLCD, moderate low-carbohydrate diet; SD, standard deviation. Figure 12 Forest plot for triglycerides changes between moderate low-carbohydrate diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; LFD, low-fat diet; MLCD, moderate low-carbohydrate diet; SD, standard deviation; TG, triglycerides.
risk and mortality rate 106 ; the Framingham Offspring Study 107 ; and the 11-year follow-up of the EPIC (European Prospective Investigation Into Cancer and Nutrition) Norfolk prospective population study. 108 This study quantified the risk associated with these lipid parameters for each level of LDL-C, from low (<2.59 mmol/L [100 mg/dL]) to high (>4.14 mmol/L [160 mg/dL]), in nonfasting samples. 108 In addition, analysis of pooled data from 9 RCTs on individuals with coronary artery disease undergoing serial intravascular ultrasonography, found that the lower TC/HDL-C ratio lowers the risk of major adverse cardiovascular events and lowers coronary atheroma progression rates. 109 The above evidence points to the residual risk when LDL-C-lowering treatments have failed to reduce cardiovascular events, and recent review articles suggest focus should turn to drug or diet treatment other than LDL-C lowering. 110, 111 In the light of these consistent findings, it has been proposed that non-HDL-C be routinely used as a cost-effective target in prevention and treatment of CVD risk. 109, 112 Thus, when assessing the CVD risk of this negligible increase in total LDL-C concentration produced by the CRDs, the marked increase in HDL-C in parallel to a marked decrease of TG with an overall neutral effect on TC, as found in the current meta-analysis, must be acknowledged.
The strategy to target LDL-C concentration as a primary CVD risk marker also disregards the heterogeneity of LDL particle number (LDL-P) and size as a function of atherogenecity, an important indicator particularly when LDL-C is not elevated. Namely, sdLDL particles (phenotype B) are more strongly associated with CVD outcomes than the lbLDL particles (phenotype A). 24, 25, 113, 114 The sdLDL particles are characterized by a longer plasma residence time, which results in higher particle oxidation and glycation, further reduction in size, and increased accumulation within arterial intima. 26, 113 Increased concentrations of sdLDL particles produced by delipidated larger atherogenic VLDL and large LDL and direct de novo hepatic production correlate with increasing TG and decreasing HDL-C levels. 25 Hence, increased TG concentration and higher TG/HDL-C ratios are superior predictors of an increasingly atherogenic LDL phenotype (phenotype B) than LDL-C, as it indicates higher levels of remnant lipoprotein particle cholesterol along with higher non-HDL-C and LDL density. 114, 115 Further, recent evidence suggests that apo-B and LDL-P concentration are superior to LDL-C and Figure 13 Forest plot for total cholesterol changes between carbohydrate-restricted diet and low-fat diet at 6, 12, and 24 months compared with baseline (mmol/L). Abbreviations: CI, confidence interval; CRD, carbohydrate-restricted diet; LFD, low-fat diet; SD, standard deviation.
non-HDL-C for assessment of CVD risk, 116 particularly among individuals with metabolic syndrome and insulin resistance, as found in the Framingham Heart Study 117 and in the cohort of the Quebec Cardiovascular Study. 118 The concordance/discordance analysis of plasma apo-B and LDL-P in 2 large retrospective cohorts shows that the discordance of LDL-P > apo-B is associated with sdLDL particle size, insulin resistance, and increased systemic inflammation. 119 Evidence regarding the effect of CRDs on LDL-P size and apo-B in the published literature is scarce, which was also revealed during this study. In the presented systematic review, decreased LDL peak density was reported by Morgan et al 90 only among participants following the Atkins diet when compared with the control, whereas decreased VLDL-C concentrations were found by Foster et al 86 These findings, although in favor of the VLCD, are not yet sufficient to make a meaningful judgment because more large RCTs with longer duration are necessary in order to compare and critically discuss these variables. However, the results of the RCT conducted by Sharman et al 120 show that a short-term (6-wk) hypoenergetic VLCD (<10% CHO TEI) led to improvement of cardiometabolic risk factors: increased mean and peak LDL-P size along with reduced fasting serum TG, TG/HDL-C ratio, postprandial lipemia, serum glucose, and insulin resistance in overweight men. 120 Similar findings-namely, increase in peak LDL-P size, a shift toward lbLDL in participants who started with a predominance of sdLDL-P, and overall improvement of CVD and diabetic risk markers after a 6-week KD-intervention in normolipidemic men with normal body weight 121 and after 12 weeks in participants with atherogenic dyslipidemia 11 -were found. The main argument against low-carbohydrate, high-fat diets is the potential adverse effect on the TC and LDL-C levels as a result of a relative or absolute increase in dietary SFAs due to CHO restriction, 4, 7, 14 although the magnitude of the effect shows variations in constellation to the specific diet quality and individual susceptibility. 5, 122, 123 Macronutrient dietary content with SFA intake is almost unavoidable because these fatty acids are present in all fat-containing foods (dairy products, meats, egg yolk, and in some vegetable fats and oils). Saturated fatty acids are nonuniform compounds, and their metabolic effects and potency to alter plasma lipids and lipoproteins depend on the composition of the SFA. As an illustration, evidence suggests that palmitate increases LDL-C and the LDL-C/HDL-C ratio and may enhance thrombogenesis, whereas stearate does not affect these lipoproteins; laurate increases LDL-C and HDL-C levels and decreases TG concentrations and the TC/HDL ratio. 124, 125 Despite the persisting belief, saturated fats per se are not robustly linked with increased all-cause mortality, CVD risk, ischemic stroke, or type 2 diabetes, as concluded in several recent meta-analyses and systematic reviews. 6, 20, 21 Although associated with increased LDL-C concentration, higher SFA intake mainly increases the less atherogenic lbLDL, 126, 127 confirmed also in an RCT among participants assigned to a high-fat (46% fat) compared with a low-fat (24% fat) diet for 6 weeks. 128 Conversely, partial replacement of dietary SFAs with CHO, particularly with fructose and sucrose, results in production of elevated sdLDL-P and overall unfavorable effects on the lipid profile, impaired glucose tolerance, and insulin resistance. 14, 122, 129, 130 In other words, by shifting sdLDL-P toward lbLDL (phenotype B to A), dietary SFAs seem to be protective against the effect of CHO.
Very little data are available on the effects of different amounts of SFAs on cardiometabolic risk factors in participants following a CRD. Krauss et al 71 found an initial reduction in TG, apo-B, LDL-C, sdLDL, and TC/ HDL cholesterol and an increased LDL peak diameter in individuals undergoing low/moderate carbohydrate intake (26% CHO) with different amounts of SFAs (7%-9% and 15%) during weight loss. However, after subsequent weight loss and weight stabilization, authors reported that improvements of these parameters were greater with the 54% CHO diet. Nevertheless, this clearly confirms that a moderate short-term CHO restriction still has the potential to improve atherogenic dyslipidemia, even in the absence of weight loss or in the presence of SFAs, whereas the LFD seems to require weight loss for its effective improvement, as argued by Feinman and Volek. 27 Hence, based on the above supporting evidence, the fear that CRDs might have adverse health effects due to increased consumption of saturated fats in particular would appear to be groundless. This is also pointed out in several reviews. 7, 9, 14 Dietary guidelines do not only shift the population away from SFAs and toward increased CHO intake, but they also encourage replacement of SFAs with PUFAs, without stating any specific type of PUFA. The pooled effects of a meta-analysis of RCTs 131 and 11 cohort studies 132 provide evidence that substituting SFAs with PUFAs reduces CVD events. However, substitution of SFAs and trans-fats with n-6 PUFAs without increasing n-3 PUFAs decreases HDL-C and increases oxidized LDL, resulting in an increased risk of all-cause mortality (mainly cancer, CVD, and coronary heart disease), as reported in the meta-analysis of Ramsden et al. 133 Thus, research and concerns should be more focused on the dietary guidelines that suggest replacing SFAs with a specific dietary PUFA, as the beneficial claims regarding PUFAs in general may be even harmful, as recently suggested. 14, 122, 130 The macronutrient contents of both the CRDs and the LFDs in the RCTs included in this meta-analysis were not clearly described because the interventions were performed on free-living adults fed ad libitum. Nevertheless, the findings of this meta-analysis in light of the presented to date available evidence demonstrate lower non-HDL-C, and lower TG/HDL-C and TC/HDL-C ratios, supporting the claim that CRDs, especially VLCDs, are more effective in the long-term reduction of CVD risk markers. Moreover, findings also suggest that the LFD, in fact, presents a potential risk because it contributes toward increased atherogenic dyslipidemia.
Strengths and limitations
This is the first meta-analysis that compares the longterm effects of CRDs versus LFDs on LDL-C levels in adults. Its strength lies in the inclusion of large RCTs (n > 100 randomized participants) because they have more power to detect intervention effects and are more likely to generate conclusions that can be generalized. Further, the duration of follow-up was 6-24 months, which enabled comparison of intervention effects at 3 points (6, 12, and 24 months) compared with the baseline values. Separating the CRD arm into VLCD and MLCD allowed the estimation, when possible, of the long-term effects of CRDs with different CHO content on LDL-C and other lipid parameters. However, this study has several limitations. The trials were performed on free-living participants; hence the macronutrient content of both the CRD and the LFD arms remains unknown, making it impossible to separately investigate the effects of the macronutrient groups (CHO, lipids, and proteins) and/or their subgroups on the outcomes of interest. Diet compliance was assessed via food diaries and 24-h diet recalls, which may result in biased association due to inaccurate reporting in the trials 134, 135 and subsequent discrepancies in effect estimates in the meta-analysis, 136 which cannot be detected via the Cochrane Risk of Bias Tool.
Attrition rates between the CRD and the LFD were relatively similar. Adherence decreased after 6 months regardless of the type of intervention. This, to some extent, might explain the more distinct changes of all parameters during the first 6 months of intervention as participants tend to return to their baseline dietary habits, an outcome outlined in the long-term RCTs included in this research. [86] [87] [88] This has also been confirmed in the 3-year follow-up of an RCT, 51 which found nonsignificant differences in carbohydrate consumption after 36 months between participants following either a CRD or an LFD. Hence, behavioral treatments to increase long-term compliance appear to be as important as the composition of the diet in prevention and treatment of CVD risk. Last, increased LDL-C may be an artifact due to the overestimation in trials where it is calculated by the Friedewald formula 94 ; in cases when the TG level falls, as happens among individuals on CRDs, even if TC and HDL-C remain unchanged, calculated LDL-C shows an increased level. 137 
CONCLUSION
The overall picture of this study demonstrates that CHO restriction, especially the VLCD, shows superiority over the LFD in improving cardiometabolic risk markers due to superior effects on HDL-C and TG, with only a negligible effect on LDL-C and no effect on TC. These favorable outcomes from the CRD should be considered for the prevention and management of dyslipidemia in population groups at higher risk of cardiovascular disease (eg, those with obesity/overweight, metabolic syndrome, prediabetes, and type 2 diabetes). The results of the presented meta-analysis suggest that the current guidelines should consider the latest evidence and CHO restriction should be included as an alternative for individuals with increased cardiometabolic risk. In general, the number of well-designed large RCTs that compare the long-term effects between the CRD and LFD on cardiometabolic risk markers in overweight and obese adults is very small. Large and longterm RCTs with emphasis on psychosomatic experiences of patients and their views on motivation to undergo diet change, focus on the quality and quantity of dietary macronutrients, and more accurate assessment of the lipid profile (LDL and HDL subfractions and particle number, concentration of apolipoproteins) and inflammatory markers are warranted. In addition, metabolomics analysis linking to the hallmark metabolite concentrations would provide an insight on a molecular level regarding interindividual variation in response to the same dietary exposure and understanding of contradictions in data findings. Considering the epidemics of obesity and obesity-related comorbidities, new nutritional approaches and more focused innovative interventions are needed in order to achieve lasting behavioral changes among population groups at higher cardiometabolic risk (eg, those with obesity/overweight, metabolic syndrome, prediabetes, type 2 diabetes, and CVD).
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